Skip to content
lifestyle.brightsfuture.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Vaxcyte, Inc.
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
August 5, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
July 8, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
June 2, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 8, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
April 7, 2026
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
March 23, 2026
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
March 18, 2026
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
March 10, 2026
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
March 9, 2026
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
March 9, 2026